Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IUX7
UPID:
AEBP1_HUMAN
Alternative names:
Aortic carboxypeptidase-like protein
Alternative UPACC:
Q8IUX7; Q14113; Q59ER7; Q6ZSC7; Q7KZ79
Background:
Adipocyte enhancer-binding protein 1, also known as Aortic carboxypeptidase-like protein, plays a crucial role in the body's extracellular matrix organization and remodeling. It acts as a positive regulator of collagen fibrillogenesis, essential for maintaining the structural integrity of connective tissues. Additionally, it influences adipocyte proliferation and differentiation, and enhances macrophage inflammatory responsiveness through NF-kappa-B activity regulation.
Therapeutic significance:
The protein's involvement in Ehlers-Danlos syndrome, classic-like, 2, a connective tissue disorder characterized by severe joint and skin laxity, osteoporosis, and delayed wound healing, underscores its therapeutic significance. Understanding the role of Adipocyte enhancer-binding protein 1 could open doors to potential therapeutic strategies for managing and treating this syndrome and its associated complications.